Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
Atsushi HiraokaTakashi KumadaKazuya KariyamaToshifumi TadaJoji TaniShinya FukunishiMasanori AtsukawaMasashi HirookaKunihiko TsujiToru IshikawaKoichi TakaguchiEi ItobayashiKazuto TajiriNoritomo ShimadaHiroshi ShibataHironori OchiKazuhito KawataSatoshi YasudaHidenori ToyodaHideko OhamaKazuhiro NousoAkemi TsutsuiTakuya NaganoNorio ItokawaKorenobu HayamaTaeang AraiMichitaka ImaiYohei KoizumiShinichiro NakamuraKouji JokoKojiro MichitakaYoichi HiasaMasatoshi Kudonull nullPublished in: Journal of gastroenterology and hepatology (2020)
Pre-sarcopenia was shown to be a significant prognostic factor in patients treated with lenvatinib for u-HCC.